Iconic Therapy for the reduction of borderline personality disorder symptoms among suicidal youth: a preliminary study

Silvia Hurtado-Santiago, José Guzmán-Parra, Fermín Mayoral, Rosa M Bersabé, Silvia Hurtado-Santiago, José Guzmán-Parra, Fermín Mayoral, Rosa M Bersabé

Abstract

Background: Iconic therapy (IT) is a new therapy that uses images to teach skills with the aim of improving the symptoms of borderline personality disorder. Preliminary results are promising, and there is indication that IT may be effective. The purpose of this preliminary study was to test the effectiveness of IT compared to a psychological supportive intervention (SI).

Methods: The study was carried out at the University Regional Hospital of Malaga. Young patients (N = 40; 15-30 years) with suicidal or parasuicidal behavior and borderline personality traits were randomized into IT (N = 20) or SI (N = 20). The main outcome variable was a change in the symptoms of borderline personality disorder (BSL-23) at the end of treatment. The secondary outcome variables were suicidal ideation and behavior, self-harm, the need for medication, the number of visits to mental health professionals, maladaptive behavior, satisfaction with therapy and perceived improvement, both at the end of the intensive treatment and at the 12-month follow-up.

Results: As expected, the two therapies produced a reduction in BPD symptoms at 10 weeks post-treatment and at the 12-month follow-up. Contrary to expectation, there were no statistically significant differences in the effectiveness of the two therapies (p > 0.05). However, at the 12-month follow-up, the effect sizes for the difference between the effectiveness of the two therapy groups on BSL-23 scores (d = 0.33) and on maladjustment to daily life (d = 0.39) was found to exceed the commonly used convention for a small effect (d = 0.20). Besides, participants in the IT group showed greater satisfaction with therapy than those who received SI. The mean difference between groups was statistically significant after the 10-week treatment period (p < .01), with a large effect size (d = 1.11). Nevertheless, this difference was not maintained at the 12-month follow-up (p > .05), although the effect size for this analysis (d = 0.34) was found to exceed a small effect.

Conclusions: This preliminary study did not find a statistically significant difference in the effectiveness of the two therapies, probably due to the small sample of participants, but there are some indicators (effect sizes) suggesting that perhaps IT may be superior for reducing BPD symptoms and maladjustment in daily life. Future studies with larger samples and comparisons with established treatments for borderline personality disorder are necessary to confirm that IT effects are significant and persistent in the long term.

Trial registration: ClinicalTrials.gov identifier: NCT03011190 . First posted 05/01/2017. Last update posted 15/05/2018.

Keywords: Borderline personality disorder; Clinical trial; Iconic therapy; Psychological therapy; Suicide.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart
Fig. 2
Fig. 2
Mean BSL-23 scores in each therapy group, at the three assessment moments

References

    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5(TM)) Arlington, VA: American Psychiatric Publishing; 2013.
    1. Arens EA, Stopsack M, Spitzer C, Appel K, Dudeck M, Völzke H, et al. Borderline personality disorder in four different age groups: a cross-sectional study of community residents in Germany. J Personal Disord. 2013;27(2):196–207. doi: 10.1521/pedi.2013.27.2.196.
    1. Bozzatello P, Rocca P, Baldassarri L, Bosia M, Bellino S. The role of trauma in early onset borderline personality disorder: a biopsychosocial perspective. Front Psichiatr. 2021.
    1. Yalch MM, Hopwood CJ, Fehon DC, Grilo CM. The influence of borderline personality features on inpatient adolescent suicide risk. Personal Disord Theory Res Treat. 2014;5(1):26–31. doi: 10.1037/per0000027.
    1. Banzhaf A, Ritter K, Merkl A, Schulte-Herbrüggen O, Lammers CH, Roepke S. Gender differences in a clinical sample of patients with borderline personality disorder. J Personal Disord. 2012;26(3):368–380. doi: 10.1521/pedi.2012.26.3.368.
    1. Chanen AM, McCutcheon L. Prevention and early intervention for borderline personality disorder: Current status and recent evidence. Vol. 202, British Journal of Psychiatry. 2013.
    1. Chanen AM, McCutcheon LK, Jovev M, Jackson HJ, McGorry PD. Prevention and early intervention for borderline personality disorder. Vol. 187, The Medical journal of Australia. 2007.
    1. Wong J, Bahji A, Khalid-Khan S. Psychotherapies for adolescents with subclinical and borderline personality disorder: a systematic review and Meta-analysis. Can J Psychiatr. 2019.
    1. NICE . Borderline personality disorder: recognition and management. 2009.
    1. Cristea IA, Gentili C, Cotet CD, Palomba D, Barbui C, Cuijpers P. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2017.
    1. Davidson KM, Tran CF. Impact of treatment intensity on suicidal behavior and depression in borderline personality disorder: a critical review. J Personal Disord. 2014;28(2):181–197. doi: 10.1521/pedi_2013_27_113.
    1. Paris J. Stepped care: an alternative to routine extended treatment for patients with borderline personality disorder. Psychiatr Serv. 2013;64(10):1035–1037. doi: 10.1176/appi.ps.201200451.
    1. Mcclure G, Hawes DJ, Dadds MR. Borderline personality disorder and neuropsychological measures of executive function: a systematic review. Personal Ment Health. 2016.
    1. Winter D. Attention to emotional stimuli in borderline personality disorder - a review of the influence of dissociation, self-reference, and psychotherapeutic interventions. Vol. 3, Borderline Personality Disorder and Emotion Dysregulation. 2016.
    1. Vannucci M, Pelagatti C, Chiorri C, Mazzoni G. Visual object imagery and autobiographical memory: object imagers are better at remembering their personal past. Memory. 2016;24(4):455–470. doi: 10.1080/09658211.2015.1018277.
    1. Weßlau C, Cloos M, Höfling V, Steil R. Visual mental imagery and symptoms of depression – results from a large-scale web-based study. BMC Psychiatry. 2015;15(1):308. doi: 10.1186/s12888-015-0689-1.
    1. Gendlin E. Focusing. Psicoterapia. 1969;6(1):4–15.
    1. Meichenbaum D. Manual de inoculación de estrés. Barcelona; Martrinez Roca (original 1985); 1987.
    1. Calkins, S.D., Gill, K.L., Johnson, M.C. &Smith CL. Emotional reactivity and emotional regulation estrategies as predictors of social behavior with peers during toddlerhood. J Soc Dev. 1999;8(310–334).
    1. D’Zurilla TJ, Goldfried MR. Problem solving and behavior modification. J Abnorm Psychol. 1971;78(1):107–126. doi: 10.1037/h0031360.
    1. Goldstein AP. Sprafkin. Gershaw, N.J. & Klein P. Habilidades sociales y autocontrol en la adolescencia. Un programa de enseñanza: R.P; 1989.
    1. Santiago S. Tratando … inestabilidad emocional. Terapia Icónica. Vol. 3a ed. Madrid: Recursos terapéuticos, Ed. Pirámide; 2013.
    1. Millon T, Davis R. Trastornos de la personalidad. Más allá del DSM-IV. Barcelona: Masson; 1998.
    1. Kovács LN, Schmelowszky Á, Galambos A, Kökönyei G. Rumination mediates the relationship between personality organization and symptoms of borderline personality disorder and depression. Pers Individ Dif [Internet]. 2021 Jan 1 [cited 2020 Sep 8];168:110339. Available from:
    1. Beck, A. T & Freeman A. beck y freeman terapia cognitiva de los trastornos de personalidad [Internet]. Paidós. 1995 [cited 2020 Apr 28]. Original, 1992. Available from:
    1. Young, J & Swift W. Schema- focused Cognitive Therapy for personality disorders. Int Cogn Ther Newsl. 1988;4(13–18).
    1. Hope NH, Wakefield MA, Northey L, Chapman AL. The association between locus of control, emotion regulation and borderline personality disorder features. Pers Ment Heal. 2018;12(3):241–251. doi: 10.1002/pmh.1419.
    1. Beblo T, Mensebach C, Wingenfeld K, Rullkoetter N, Schlosser N, Driessen M. Subjective memory complaints and memory performance in patients with borderline personality disorder. BMC Psychiatr. 2014;14:1. doi: 10.1186/s12888-014-0255-2.
    1. Santiago-López S, Castro-Lucena S, Cañamero-Peral D, Godoy-Avila A, Valverde-Thomsem S, Artacho-Gómez V, Marcos-Márquez CM. Terapia Icónica en Inestabilidad Emocional Estudio Preliminar. Cuad Psiquiatr Comunitaria. 2005;5(2):151–164.
    1. Costa-Ortíz A. Terapia icónica grupal para el tratamiento de la inestabilidad emocional en la adolescencia. Estudio piloto en un Centro de Atención Primaria (CAP). ISEP Sci. 2012;(3):4–27.
    1. Hurtado-Santiago S, Guzmán-Parra J, Bersabé RM, Mayoral F. Effectiveness of iconic therapy for the reduction of borderline personality disorder symptoms among suicidal youth: Study protocol for a randomised controlled trial. BMC Psychiatr. 2018;18:1. doi: 10.1186/s12888-018-1857-x.
    1. Soler J, Vega D, Feliu-Soler A, Trujols J, Soto Á, Elices M, et al. Validation of the Spanish version of the borderline symptom list, short form (BSL-23). BMC Psychiatr. 2013;13.
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011.
    1. Association AP . Diagnostic and statistical manual of mental disorders. 5. D.C.: Washington; 2013.
    1. (PDF) Escala de inadaptación (EI): Propiedades psicométricas en contextos clínicos [Internet]. [cited 2019 Dec 14]. Available from:
    1. Beecham J, Knapp M. Costing Psychiactric interventions. In: Measuring Mental Health Needs. 2001.
    1. Borkovec TD, Nau SD. Credibility of analogue therapy rationales. J Behav Ther Exp Psychiatry. 1972;3(4):257–260. doi: 10.1016/0005-7916(72)90045-6.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2. SHillsdale, NJ: Lawrence Earlbaum Associates; 1988.
    1. Laporte L, Paris J, Bergevin T, Fraser R, Cardin JF. Clinical outcomes of a stepped care program for borderline personality disorder. Personal Ment Health. 2018;12(3):252–264. doi: 10.1002/pmh.1421.
    1. Grenyer B.F.S; Lewis K. L FM& KB. Treatment of personality disorder using a whole of service stepped care approach: a cluster randomized controlled trial. 10.1371/journal.pone0206472 .
    1. McMain SF, Guimond T, Barnhart R, Habinski L, Streiner DL. A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder. Acta Psychiatr Scand. 2017;135(2):138–148. doi: 10.1111/acps.12664.
    1. Soler J, Pascual JC, Tiana T, Cebrià A, Barrachina J, Campins MJ, et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behav Res Ther. 2009;47(5):353–358. doi: 10.1016/j.brat.2009.01.013.
    1. McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. Am J Psychiatry. 2009;166(12):1365–1374. doi: 10.1176/appi.ajp.2009.09010039.
    1. Laurenssen EMP, Luyten P, Kikkert MJ, Westra D, Peen J, Soons MBJ, et al. Day hospital mentalization-based treatment v. specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychol Med. 2018;48(15):2515–2521. doi: 10.1017/S0033291718000132.
    1. Chanen AM, Jackson HJ, McCutcheon LK, Jovev M, Dudgeon P, Hok PY, et al. Early intervention for adolescents with borderline personality disorder using cognitive analytic therapy: randomised controlled trial. Br J Psychiatry. 2008;193(6):477–484. doi: 10.1192/bjp.bp.107.048934.
    1. Andreasson K, Krogh J, Wenneberg C, Jessen HKL, Krakauer K, Gluud C, et al. Effectiveness of dialectical behavior therapy versus collaborative assessment and management of suicidality treatment for reduction of self-harm in adults with borderline personality traits and disorder —a randomized observer- blinded clinical trial. Depress Anxiety. 2016;33(6):520–530. doi: 10.1002/da.22472.
    1. Cottraux J, Note ID, Boutitie F, Milliery M, Genouihlac V, Yao SN, et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder: two-year follow-up of a controlled pilot study. Psychother Psychosom. 2009;78(5):307–316. doi: 10.1159/000229769.
    1. Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF Evaluating three treatments for borderline personality disorder: a multiwave study. Am J Psychiatry. 2007;164(6):922–928. doi: 10.1176/ajp.2007.164.6.922.
    1. Gunderson JG, Stout RL, McGlashan TH, Shea MT, Morey LC, Grilo CM, et al. Ten-year course of borderline personality disorder: psychopathology and function from the collaborative longitudinal personality disorders study. Arch Gen Psychiatry. 2011.
    1. Davidson KM, Tyrer P, Norrie J, Palmer SJ, Tyrer H. Cognitive therapy v. usual treatment for borderline personality disorder: prospective 6-year follow-up. Br J Psychiatry. 2010;197(6):456–462. doi: 10.1192/bjp.bp.109.074286.
    1. Blum N. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: A randomized controlled trial and 1-year follow-up (American Journal of Psychiatry (2008) 165 (468–478) DOI: 10.1176/appi.ajp. American Journal of Psychiatry. 2008.
    1. Stanley B, Brodsky B, Nelson JD, Dulit R. Brief Dialectical Behavior Therapy (DBT-B) for suicidal behavior and non-suicidal self injury. Arch Suicide Res [Internet]. 2007 Nov [cited 2020 Jul 11];11(4):337–41. Available from:
    1. Chanen AM, Berk M, Thompson K. Integrating early intervention for borderline personality disorder and mood disorders. Vol. 24, Harvard Review of Psychiatry. 2016. p. 330–41.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi